For all those who continue to promote their propaganda that exposure to mold toxins only causes allergies OR only the very seriously ill would be affected – note these words – “increasingly prevalent” and “Aspergillus” and “mold infection” and “invasive” and “increasing in frequency” and “high morbility rate” and for one of their favorite arguments which is that this only happens to people with serious underlying risk factors (such as cancer) and rarely to “healthy” individuals – note the word – “particularly” before underlying risk factors. That just means they are more likely to become ill if exposed to these molds. COMMON SENSE. There are other risk factors that “healthy” people have that put them in an underlying risk factor group – (besides just breathing) – such as asthma, recovering from a surgery, a lowered immune system for any number of reasons, mitral valve prolaspe (high risk of a valve infection from fungus just like the higher risk factor from bacteria) and etc., etc., etc. . AND THEN THERE ARE INFANTS AND CHILDREN WHO ARE AT RISK PERIOD BECAUSE OF THEIR NOT FULLY DEVELOPED IMMUNE SYSTEM.
Some of those behind the propaganda that mold toxins generally pose no harm are the owners and management companies of properties who are aware that they have a serious mold problem yet try to conceal and deny it. They want you to believe their propaganda so as to not be held accountable when it is exposed. They need to promote this propaganda because, for instance in my case, when they lease an apartment filled with years of mold growth in the HVAC system and through out the apartment and we then find out – they want to say it could not cause anything other than some allergy symptons. Of course, thats after they deny over and over they have no knowledge of mold. Besides the fact that we were breathing, I have mitral valve prolaspe, my daughter had an open wound from a surgery on her leg (easy access for aspergillus and other molds blowing from the vents to get in the wound), AND THE BABY WAS JUST AT RISK BACAUSE HE WAS A BABY. HE HAS ASTHMA NOW BUT NOT BEFORE MOVING IN THERE. The fact that there is overwhelming documented evidence that they knew of the mold in this place (or should have known) is another subject (crime). Those referred to are the owner or owners of Jefferson Lakes Apartments in Baton Rouge Louisiana at the time we moved in and the management company Riverstone Residential. Those guilty of continuing to allow people to move into this place are the owners after the complex was sold in 2007, The Louisiana Housing Finance Agency and Riverstone Residential. katy
Note these phrases from this study –
“Although Candida species remain a relevant cause of IFI, (invasive fungal infection) other organisms (particularly moulds) have become increasingly prevalent”
“In particular, Aspergillus species are the leading cause of mould infections although other other moulds including Fusarium species and Zygomycetes are increasing in frequency, and are associated with a high mortality rate.”
Published online: 19 July 2008
This is the abstact of the article that has to be purchased.
Invasive fungal infections (IFIs) are an important cause of morbidity and mortality, particularly in patients with underlying risk factors (e.g., neutropenia, cancer chemotherapy, transplantation, AIDS). Although Candida species remain a relevant cause of IFI, other organisms (particularly moulds) have become increasingly prevalent. In particular, Aspergillus species are the leading cause of mould infections although other moulds including Fusarium species and Zygomycetes are increasing in frequency, and are associated with a high mortality rate. Options available for the prevention and treatment of these infections include standard and liposomal formulations of amphotericin B, but toxicity concerns limit their use; fluconazole is effective for the prevention and treatment of candidiasis but its inactivity against moulds and increasing resistance are limiting factors. Newer azoles, particularly voriconazole and posaconazole, have an enhanced spectrum of activity that includes Candida species, Aspergillus species, Cryptococcus species, dimorphic fungi, Fusarium species, and, for posaconazole, Zygomycetes. Recent data suggest that these agents are highly effective in a variety of clinical settings. Echinocandins have good activity against Candida species and Aspergillus species but their spectrum generally does not include Fusarium species, Cryptococcus species, Trichosporon species, Zygomycetes, and dematiaceous moulds. While these agents are unlikely to exhibit cross-resistance with polyenes or azoles, they must be administered intravenously. Knowledge of the pathogenesis of IFIs and the activity, efficacy, and limitations of available treatment options will allow the selection of an appropriate antifungal agent for individual patients.